GlassScriptPhysician profile
Frances Marrero Barrera
NPI 1275049488
$2,255.87
in general payments reported to CMS, 2019-2025
11 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $126 · 2023: $812 · 2024: $271 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.44 |
| Education | $109.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $768.15 | 2023-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Mallinckrodt Hospital Products INC. | $453.34 | 2025 | Acthar |
| Alcon Puerto Rico INC | $320.72 | 2022-2025 | Clareon, Unity |
| Abbvie INC. | $187.38 | 2022-2025 | |
| Glaukos Corporation | $149.08 | 2023 | |
| Horizon Therapeutics Plc | $115.40 | 2023 | Tepezza |
| Rxsight INC | $106.51 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Ani Pharmaceuticals, INC. | $57.94 | 2025 | Purified Cortrophin Gel |
| Alcon Vision LLC | $51.93 | 2024 | Clareon |
| Genentech USA, INC. | $27.09 | 2025 | Vabysmo |
| Oyster Point Pharma, INC. | $18.33 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Marrero Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.